Skip to main content
Journal cover image

Underuse of aspirin in a referral population with documented coronary artery disease.

Publication ,  Journal Article
Califf, RM; DeLong, ER; Ostbye, T; Muhlbaier, LH; Chen, A; LaPointe, NA; Hammill, BG; McCants, CB; Kramer, JM
Published in: Am J Cardiol
March 15, 2002

Despite substantial evidence that antiplatelet therapy saves lives and reduces adverse events in patients with coronary artery disease (CAD), use of the most widely available and lowest cost antiplatelet agent, aspirin, continues to be disappointingly low. In a large database of patients with known CAD, we (1) explored trends in the use of aspirin over time, (2) characterized patients most likely to take aspirin regularly, and (3) estimated the effectiveness of aspirin use by examining long-term outcomes. Using patients entered in the Duke Databank for Cardiovascular Diseases, we explored the use of aspirin from 1969 to 1999. More than 25,000 patients were sent a questionnaire that included several questions about medication use, including 1 question specifically about aspirin. Patients who failed to respond to the questionnaire received a follow-up telephone call. Aspirin use increased substantially over the most recent 4 years in the study, from 59% in 1995 to 81% in 1999. Predictors of aspirin use included younger age, male sex, being a nonsmoker, and having had a myocardial infarction or revascularization procedure. Patients who never took aspirin had a risk ratio for death of 1.85 compared with patients who regularly took aspirin. Despite the well-known beneficial effects of aspirin, too many patients without contraindications to aspirin fail to take it regularly. The health care system currently lacks effective methods to ensure that patients who have CAD have adequate follow-up concerning aspirin use.

Duke Scholars

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

March 15, 2002

Volume

89

Issue

6

Start / End Page

653 / 661

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Sex Factors
  • Predictive Value of Tests
  • Platelet Aggregation Inhibitors
  • North Carolina
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Califf, R. M., DeLong, E. R., Ostbye, T., Muhlbaier, L. H., Chen, A., LaPointe, N. A., … Kramer, J. M. (2002). Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol, 89(6), 653–661. https://doi.org/10.1016/s0002-9149(01)02335-9
Califf, Robert M., Elizabeth R. DeLong, Truls Ostbye, Lawrence H. Muhlbaier, Anita Chen, Nancy Allen LaPointe, Bradley G. Hammill, Charles B. McCants, and Judith M. Kramer. “Underuse of aspirin in a referral population with documented coronary artery disease.Am J Cardiol 89, no. 6 (March 15, 2002): 653–61. https://doi.org/10.1016/s0002-9149(01)02335-9.
Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002 Mar 15;89(6):653–61.
Califf, Robert M., et al. “Underuse of aspirin in a referral population with documented coronary artery disease.Am J Cardiol, vol. 89, no. 6, Mar. 2002, pp. 653–61. Pubmed, doi:10.1016/s0002-9149(01)02335-9.
Califf RM, DeLong ER, Ostbye T, Muhlbaier LH, Chen A, LaPointe NA, Hammill BG, McCants CB, Kramer JM. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002 Mar 15;89(6):653–661.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

March 15, 2002

Volume

89

Issue

6

Start / End Page

653 / 661

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Sex Factors
  • Predictive Value of Tests
  • Platelet Aggregation Inhibitors
  • North Carolina
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Humans